Indivior Share Forecast, Price & News

GBX 134
+0.80 (+0.60 %)
(As of 04/16/2021 12:00 AM ET)
Today's Range
Now: GBX 134
50-Day Range
MA: GBX 126.71
52-Week Range
Now: GBX 134
Volume704,099 shs
Average Volume1.34 million shs
Market Capitalization£984.39 million
P/E RatioN/A
Dividend YieldN/A
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company's products focuses on treating substance use disorder, opioid use disorder, and schizophrenia. It offers SUBLOCADE injection for subcutaneous use; SUBOXONE sublingual film; and PERSERIS for extended-release injectable suspension, as well as sells legacy analgesic products that include Temgesic, Burpex, and Buprenex. The company is also involved in finance activities. It operates in approximately 40 countries worldwide. Indivior PLC was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
Indivior logo

Industry, Sector and Symbol

Industry Drugs - Generic
Year FoundedN/A



Sales & Book Value

Annual Sales£647 million
Cash FlowGBX 114.02 per share
Book ValueGBX 11.20 per share



Market Cap£984.39 million
Next Earnings DateN/A
OptionableNot Optionable


Drugmaker Indivior warns pandemic pain to extend into 2021
February 18, 2021 |  finance.yahoo.com
See More Headlines


Overall MarketRank

1.38 out of 5 stars

Analyst Opinion: 3.5Community Rank: 3.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
GBX 134
+0.80 (+0.60 %)
(As of 04/16/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive INDV News and Ratings via Email

Sign-up to receive the latest news and ratings for INDV and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Indivior (LON:INDV) Frequently Asked Questions

Is Indivior a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Indivior in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Indivior stock.
View analyst ratings for Indivior
or view top-rated stocks.

What stocks does MarketBeat like better than Indivior?

Wall Street analysts have given Indivior a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Indivior wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How has Indivior's stock been impacted by COVID-19 (Coronavirus)?

Indivior's stock was trading at GBX 46.21 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, INDV shares have increased by 190.0% and is now trading at GBX 134.
View which stocks have been most impacted by COVID-19

What price target have analysts set for INDV?

2 Wall Street analysts have issued 1 year target prices for Indivior's stock. Their forecasts range from GBX 185 to GBX 205. On average, they anticipate Indivior's stock price to reach GBX 195 in the next twelve months. This suggests a possible upside of 45.5% from the stock's current price.
View analysts' price targets for Indivior
or view top-rated stocks among Wall Street analysts.

Who are Indivior's key executives?

Indivior's management team includes the following people:
  • Mr. Mark Crossley, CEO & Exec. Director
  • Mr. Ryan Preblick, CFO & Exec. Director
  • Dr. Christian Heidbreder, Chief Scientific Officer
  • Mr. Jason Thompson, VP of Investor Relations
  • Ms. Cynthia Cetani, Chief Integrity & Compliance Officer
  • Mr. Jon Fogle, Chief HR Officer
  • Mr. Richard Simkin, Chief Commercial & Strategy Officer
  • Ms. Sue Learned, Sr. VP of Global Clinical Devel.
  • Hillel West, Chief Manufacturing & Supply Officer
  • Ms. Kathryn Hudson, Company Sec.

Who are some of Indivior's key competitors?

What other stocks do shareholders of Indivior own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Indivior investors own include Bigblu Broadband (BBB), Futura Medical (FUM), Directa Plus (DCTA), Lakehouse (LAKE), Aquila Services Group (AQSG), Benchmark (BMK), Bodycote (BOY), (CITY.L) (CITY), Deltex Medical Group (DEMG) and Kingfisher (KGF).

What is Indivior's stock symbol?

Indivior trades on the London Stock Exchange (LON) under the ticker symbol "INDV."

How do I buy shares of Indivior?

Shares of INDV and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Indivior's stock price today?

One share of INDV stock can currently be purchased for approximately GBX 134.

How much money does Indivior make?

Indivior has a market capitalization of £984.39 million and generates £647 million in revenue each year.

How many employees does Indivior have?

Indivior employs 796 workers across the globe.

What is Indivior's official website?

The official website for Indivior is indivior.com.

Where are Indivior's headquarters?

Indivior is headquartered at 103-105 Bath Road, SLOUGH, SL1 3UH, United Kingdom.

How can I contact Indivior?

Indivior's mailing address is 103-105 Bath Road, SLOUGH, SL1 3UH, United Kingdom. The specialty pharmaceutical company can be reached via phone at +44-1753-217800.

This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.